Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH

What Was Tested

Researchers studied GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.

It is well established that the central alpha 2-adrenergic agonist clonidine can enhance growth hormone (GH) secretion in humans.

This effect is most likely due to stimulation of hypothalamic growth hormone releasing hormone (GHRH) release.

Who Took Part

The study group was 12 volunteers.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this GHRH (Growth Hormone-Releasing Hormone) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the volunteers and researchers unaware of who received GHRH (Growth Hormone-Releasing Hormone).

The comparison arm used a placebo, so changes seen with GHRH (Growth Hormone-Releasing Hormone) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Antihypertensive Agents, Clonidine, Growth Hormone, Growth Hormone-Releasing Hormone and Imidazoles.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone) in 12 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.